Exclusive-US consumer safety agency to stop collecting swaths of data after CDC cuts
(Reuters) -The U.S. consumer product safety agency will stop collecting data on injuries from incidents like car accidents and adverse drug effects due to staff cuts at the CDC, according to an agency email seen by Reuters and a source familiar with the situation.
The 47-year-old National Electronic Injury Surveillance System collects data from a representative sample of 100 hospital emergency departments across the country.
Injury is the leading cause of death for Americans under 45 years old, and data from NEISS informs product recalls, safety standards and other public policy to prevent injuries and deaths.
The change is another disruption caused by President Donald Trump's elimination of 10,000 jobs at the Department of Health and Human Services, led by Robert F. Kennedy, Jr., which has upended public health research and the agency's bird flu response and drug review system. HHS has said another 10,000 people left voluntarily.
On Friday, the Consumer Product Safety Commission will stop collecting data on injuries from motor vehicle crashes, falls, alcohol, adverse drug effects, aircraft incidents, work-related injuries, and other incidents through NEISS, according to the source.
The change will reduce the program's data collection by 20% to 65%, the source said.
The CPSC did not respond to a request for comment.
For its first 22 years, NEISS collected data only on injuries linked to specific products, like lawn mowers or household chemicals.
In 2000, the U.S. Centers for Disease Control and Prevention entered into an agreement with CPSC to expand the data collection to other types of incidents, in an effort called the All Injury Program. The AIP is ending because of firings at CDC, according to an email sent to participating hospitals and data contractors on April 11.
"Unfortunately, due to the recent reductions-in-force and budget cuts across CDC's National Center for Injury Prevention and Control, the AIP supported portion of the NEISS is coming to an end very quickly," the email said.
"This will be an abrupt transition as CPSC does not have the resources to wind down AIP in an orderly and structured manner," the email said.
Some of the data collected by the NEISS-AIP program is also gathered in some form by other agencies, like the National Highway Traffic Safety Administration or the Occupational Safety and Health Administration. But the NEISS-AIP data can be more comprehensive because it captures injuries at the hospital level, said the source.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close totalling over A$439m
MELBOURNE, Australia, July 24, 2025 (GLOBE NEWSWIRE) -- Brandon Capital, Australasia's leading life sciences venture capital firm, today announced the final close of its sixth fund at A$439 million. Joining existing investors Hesta, Host Plus, CSL and QIC are the WA Government and Australia's sovereign investor in manufacturing capability, the National Reconstruction Fund Corporation (NRFC). This final close of Brandon BioCatalyst Fund Six (BB6) will see Brandon Capital continue to invest in emerging biomedical technologies with strong commercial potential, translating these exciting discoveries into high-growth firms that positively impact human health. To date, Brandon Capital has raised over A$1 billion across previous funds with notable Fund Six investments to date including AdvanCell (radiopharma), PolyActiva (glaucoma implant), Myricx Bio (ADC) and CatalYm (oncology). Dr Chris Nave, Co-Founder and Managing Partner at Brandon Capital, 'We're excited to welcome the National Reconstruction Fund Corporation to our sixth fund, joining HESTA, Hostplus, CSL, QIC and the WA Government. Closing at $439 million, BB6 is our largest fund to date, and we remain committed to advancing breakthrough biomedical innovations through our unwavering scientific rigour and disciplined capital allocation, in pursuit of exceeding our investors' expectations.' The firm has a track record of advancing its portfolio companies to commercialisation. Recent Brandon Capital portfolio company announcements include FDA approvals for a hypertension therapy from George Medicines and a left ventricular cardiac resynchronisation device developed by EBR Systems, with Q-Sera's blood collection tubes that produce high-quality serum faster and more reliably, recently approved in Japan. Brandon Capital has an active portfolio of over 30 companies with 17 in clinical trials, four advancing or in-market, a promising preclinical pipeline and several actively contributing to Australia's high-skilled manufacturing sector growth. Collectively supporting over 270 high-skilled Australian jobs are: surgical imaging innovator, OncoRes Medical, which has developed the first 'real-time' in cavity probe to improve cancer surgery outcomes; late-stage biotech PolyActiva, which is developing a long-term treatment for glaucoma, the second leading cause of blindness; needle-free patch for vaccine delivery Vaxxas, and radiopharmaceutical company AdvanCell, which is developing novel therapies for the treatment of a range of cancers. NRFC CEO David Gall said, "Medical science has long development timelines, and it is important for the NRFC to make early and considered investments in the sector to attract the talent and capital that we will need to build our local commercialisation capabilities. If we want medical science jobs and industries to exist in Australia in ten years, we need to invest in them today." Brandon Capital, headquartered in Australia with offices in the UK and US, has established a transcontinental presence that strengthens collaboration across regions. Australian portfolio companies gain access to UK/EU/US capital, expertise, and pharma networks, while international companies benefit from Australia's world-class clinical trial and research capabilities. About Brandon Capital – Brandon Capital is Australasia's leading life sciences venture capital firm, with offices in Australia, New Zealand, the US and the UK. Its unique model includes proprietary deal flow through Brandon BioCatalyst, a collaboration of over 50 of ANZ's leading medical research institutions, and its immersive corporate services structure enables portfolio companies to focus on research commercialisation. With more than 30 active companies in its portfolio, Brandon Capital has been sourcing and supporting the transition of world-leading science into world-leading businesses for nearly two decades. For further information please contact Media – AustraliaKirrily Davis, E: kdavis@ M: +61 (0)401 220228 Media - InternationalSue Charles, Charles Consultants E: M: +44 (0)7968 726585 Chris Gardner, E: Chris@ M: +44 (0)7956 031077 About the National Reconstruction Fund Corporation (NRFC) The NRFC invests to diversify and transform Australia's industry and economy. It has $15 billion to invest using direct loans, equity investments and loan guarantees. The NRFC investment mandate covers seven priority areas including value-add in resources; transport; medical science; defence capability; renewables and low emission technologies; value-add in agriculture, forestry and fisheries; and enabling capabilities. The NRFC's role is to invest in Australian businesses and projects that design, refine and make in order to transform capability, grow jobs and a skilled workforce, and diversify our economy. NRFC is a corporate Commonwealth entity, established by the National Reconstruction Fund Corporation Act 2023 (NRFC Act) in September 2023. For more information, visit
2 hours ago
The US fertility rate reached a new low in 2024, CDC data shows
NEW YORK -- The fertility rate in the U.S. dropped to an all-time low in 2024 with less than 1.6 kids per woman, new federal data released Thursday shows. The U.S. was once among only a few developed countries with a rate that ensured each generation had enough children to replace itself — about 2.1 kids per woman. But it has been sliding in America for close to two decades as more women are waiting longer to have children or never taking that step at all. The new statistic is on par with fertility rates in western European countries, according to World Bank data. Alarmed by recent drops, the Trump administration has taken steps to increase falling birth rates, like issuing an executive order meant to expand access to and reduce costs of in vitro fertilization and backing the idea of 'baby bonuses' that might encourage more couples to have kids. But there's no reason to be alarmed, according to Leslie Root, a University of Colorado Boulder researcher focused on fertility and population policy. 'We're seeing this as part of an ongoing process of fertility delay. We know that the U.S. population is still growing, and we still have a natural increase — more births than deaths,' she said. The U.S. Centers for Disease Control and Prevention released the statistic for the total fertility rate with updated birth data for 2024. In the early 1960s, the U.S. total fertility rate was around 3.5, but plummeted to 1.7 by 1976 after the Baby Boom ended. It gradually rose to 2.1 in 2007 before falling again, aside from a 2014 uptick. The rate in 2023 was 1.621, and inched down in 2024 to 1.599, according to the CDC's National Center for Health Statistics. Birth rates are generally declining for women in most age groups — and that doesn't seem likely to change in the near future, said Karen Guzzo, director of the Carolina Population Center at the University of North Carolina. People are marrying later and also worried about their ability to have the money, health insurance and other resources needed to raise children in a stable environment. 'Worry is not a good moment to have kids,' and that's why birth rates in most age groups are not improving, she said. Asked about birth-promoting measures outlined by the Trump administration, Guzzo said they don't tackle larger needs like parental leave and affordable child care. 'The things that they are doing are really symbolic and not likely to budge things for real Americans,' she said. The CDC's new report, which is based on a more complete review of birth certificates than provisional data released earlier this year, also showed a 1% increase in births — about 33,000 more — last year compared to the prior year. That brought the yearly national total to just over 3.6 million babies born. But this is different: The provisional data indicated birth rate increases last year for women in their late 20s and 30s. However, the new report found birth rate declines for women in their 20s and early 30s, and no change for women in their late 30s. What happened? CDC officials said it was due to recalculations stemming from a change in the U.S. Census population estimates used to compute the birth rate. That's plausible, Root said. As the total population of women of childbearing age grew due to immigration, it offset small increases in births to women in those age groups, she said. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Washington Post
3 hours ago
- Washington Post
Australia to reduce US beef import restrictions denounced by Trump as a ban
MELBOURNE, Australia — Australia will reduce restrictions on U.S. beef imports after U.S. President Donald Trump criticized what he described as an Australian ban on the meat, Agriculture Minister Julie Collins said. Collins said Thursday that relaxing the restrictions designed to keep Australia free of mad cow disease , also known as bovine spongiform encephalopathy or BSE, among its cattle herds would not compromise biosecurity.
